Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 57 155 sessions, September 8, 2025 to September 8, 2026
- Largest daily move
- +1300% close of February 3, 2026
- 1-year change
- -50% closing prices, September 8, 2025 to September 8, 2026
Company Description
Aridis Pharmaceuticals (OTC Link: ARDS) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $4.5K.
ARDS has declined 50.0% over the past year. The last closing price was $0.0001.
For FY2022, Aridis Pharmaceuticals reported revenue of $3.1M with net income of -$30.4M. The company operates at a net profit margin of -982.6%.
This page collects what Stock Titan holds for ARDS, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Aridis Pharmaceuticals (ARDS) closed at $0.0001 on September 8, 2026. Over the past 12 months, the price has lost 50.0%.
ARDS Metrics & Rankings
Price returns through September 8, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Aridis Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, clinical trial, fda approval. View all ARDS news →
SEC Filings
Aridis Pharmaceuticals has filed 3 recent SEC filings, including 3 Form SCHEDULE 13G/A. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ARDS SEC filings →
Financial Highlights
Aridis Pharmaceuticals generated $3.1M in revenue in FY2022, operating income reached -$30.0M (-970.3% operating margin), and net income was -$30.4M, reflecting a -982.6% net profit margin. The company generated -$29.1M in operating cash flow. With a current ratio of 0.32, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Aridis Pharmaceuticals (ARDS) currently stands at 15.5 thousand shares, representing 0.0% of the float. Since September 2025, short interest has decreased by 39.8%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Aridis Pharmaceuticals (ARDS) currently stands at 1.0 days, down 89.9% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 18.2 days.
ARDS Company Profile & Sector Positioning
Aridis Pharmaceuticals (ARDS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ARDS often look at related companies in the same sector, including Syros Pharmaceut (SYRS), Navidea Biopharm (NAVB), Tracon Pharmaceu (TCON), PaxMedica, Inc. (PXMD), and Endonovo Therape (ENDV). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ARDS's relative position within its industry.